Luigi Bolondi
University of Bologna
439 Papers
3.2K Citations
Luigi Bolondi is an academic researcher from University of Bologna. The author has contributed to research in topics: Medicine & Hepatocellular carcinoma. The author has an hindex of 81, co-authored 434 publications. Previous affiliations of Luigi Bolondi include University of Ferrara.
Chat about Author
Papers
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more
TL;DR: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Ghassan K. Abou-Alfa,Tim Meyer,Ann-Lii Cheng,Anthony B. El-Khoueiry,Lorenza Rimassa,Baek Yeol Ryoo,Irfan Cicin,Philippe Merle,Yen-Hsun Chen,Joong-Won Park,Jean-Frédéric Blanc,Luigi Bolondi,Heinz Josef Klümpen,Heinz Josef Klümpen,Stephen L. Chan,Vittorina Zagonel,Tiziana Pressiani,Min Hee Ryu,Alan P. Venook,Alan P. Venook,Colin Hessel,Anne E. Borgman-Hagey,Gisela Schwab,Robin Kate Kelley +23 more
TL;DR: Treatment with cabozantinib resulted in longer overall survival and progression‐free survival than placebo among patients with previously treated advanced hepatocellular carcinoma, and the rate of high‐grade adverse events in the cabozaninib group was approximately twice that observed in the placebo group.
2K
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
Jordi Bruix,Tadatoshi Takayama,Vincenzo Mazzaferro,Gar Yang Chau,Jiamei Yang,Masatoshi Kudo,Jianqiang Cai,Ronnie Tung-Ping Poon,Kwang Hyub Han,Won Young Tak,Han Chu Lee,Tianqiang Song,Sasan Roayaie,Luigi Bolondi,Kwan Sik Lee,Masatoshi Makuuchi,Fabricio Souza,Marie Aude Le Berre,Gerold Meinhardt,Josep M. Llovet,Josep M. Llovet +20 more
TL;DR: The data indicate that sorafenib is not an effective intervention in the adjuvant setting for hepatocellular carcinoma following resection or ablation.
983
Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) - Update 2008
Michel Claudon,David O. Cosgrove,T. Albrecht,Luigi Bolondi,M. Bosio,Fabrizio Calliada,J. M. Correas,Kassa Darge,Christoph F. Dietrich,Mirko D'Onofrio,David H. Evans,Carlo Filice,L. Greiner,K. Jäger,N. de Jong,Edward Leen,Riccardo Lencioni,D. Lindsell,Alberto Martegani,S. Meairs,Christian Pállson Nolsøe,Fabio Piscaglia,Paolo Ricci,G. Seidel,Bjørn Skjoldbye,Luigi Solbiati,L. Thorelius,François Tranquart,H. P. Weskott,T. Whittingham +29 more
- 01 Feb 2008
TL;DR: EFSUMB study group M. Claudon, D. Cosgrove, T. Tranquart, L. Thorelius, and H. Whittingham study group L. de.
Cyclin G1 Is a Target of miR-122a, a MicroRNA Frequently Down-regulated in Human Hepatocellular Carcinoma
Laura Gramantieri,Manuela Ferracin,Francesca Fornari,Angelo Veronese,Silvia Sabbioni,Chang Gong Liu,George A. Calin,Catia Giovannini,Eros Ferrazzi,Gian Luca Grazi,Carlo M. Croce,Carlo M. Croce,Luigi Bolondi,Massimo Negrini,Massimo Negrini +14 more
TL;DR: Results indicate that cyclin G1 is a target of miR-122a and expand the knowledge of the molecular alterations involved in HCC pathogenesis and of the role of miRNAs in human cancer.
879